Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2024)

Historic Preferred Stock Liabilities for Avalo Therapeutics (AVTX) over the last 3 years, with Q3 2024 value amounting to $1.7 million.

  • Avalo Therapeutics' Preferred Stock Liabilities changed N/A to $1.7 million in Q3 2024 from the same period last year, while for Sep 2024 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $28.3 million for FY2014, which is N/A changed from last year.
  • According to the latest figures from Q3 2024, Avalo Therapeutics' Preferred Stock Liabilities is $1.7 million.
  • Avalo Therapeutics' 5-year Preferred Stock Liabilities high stood at $11.5 million for Q1 2024, and its period low was $1.7 million during Q3 2024.